Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Zhi-Lu Wang"'
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Traditional angiography only displays two-dimensional images of the coronary arteries during stent implantation. However, intravascular imaging can show the structure of the vascular wall, plaque characteristics. This article aims
Externí odkaz:
https://doaj.org/article/d91874c69308431c84f1001c56b16467
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background The inflammation hypothesis of atherosclerosis has been put forward for more than 20 years. Although many animal experiments have suggested that anti-inflammatory therapy can inhibit the atherosclerotic process, the efficacy of an
Externí odkaz:
https://doaj.org/article/4a11097e484c4ccdb49df00a264eb574
Publikováno v:
Platelets, Vol 32, Iss 5, Pp 582-590 (2021)
Dual antiplatelet therapy (DAPT) is the basis of preventing stent thrombosis and ischemic events after percutaneous coronary intervention (PCI), but prolonging the duration of DAPT will increase the risk of bleeding. The optimal duration of DAPT afte
Externí odkaz:
https://doaj.org/article/b097ea42b95a4123bd8048144a67d336
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Background and ObjectiveThe de novo coronary lesions are the most common form of coronary artery disease, and stent implantation still is the main therapeutic strategy. This network meta-analysis aims to evaluate the efficacy of drug-coated balloons
Externí odkaz:
https://doaj.org/article/da94b5a42ec84efbb35a2519b7c845dc
Publikováno v:
Platelets, Vol 31, Iss 1, Pp 15-25 (2020)
Switching from a potent P2Y12 blocker to clopidogrel is not uncommon for antiplatelet therapy in patients undergoing percutaneous coronary intervention. This meta-analysis aimed to investigate the efficacy and safety of this de-escalation strategy. M
Externí odkaz:
https://doaj.org/article/b60a3bac352d4f0eac34fa0ea0257425
Publikováno v:
Journal of Interventional Cardiology, Vol 2022 (2022)
Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background. Abciximab has long-term
Externí odkaz:
https://doaj.org/article/282252c90cd645bc8a68d12846da91b6
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Background and Objective: Dual antiplatelet therapy (DAPT) is the basis for preventing ischemic events after percutaneous coronary intervention (PCI), and DAPT for 12 months has been the standard strategy recommended by the guidelines. However, patie
Externí odkaz:
https://doaj.org/article/91c367805ea1479e8c30f0cc4a568eb3
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Background: Patients with diabetes represent 20–30% of the population considered for percutaneous coronary intervention (PCI) and associate with more deleterious clinical outcome, which requires the optimal strategy of dual antiplatelet therapy (DA
Externí odkaz:
https://doaj.org/article/e103d47bcc794c68832bb2e20902bebd
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Background and Objectives: The second-generation drug-eluting stents have been used to treat chronic total occlusion lesion. However, there is limited evidence of the clinical outcomes that whether the second-generation drug-eluting stents is superio
Externí odkaz:
https://doaj.org/article/e7af976f8e43497095d8022b0d0dbbf9
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Background and Objective: The optimum duration of dual antiplatelet therapy (DAPT) remains uncertain in patients with acute coronary syndrome treated with new generation stents. This meta-analysis was performed to investigate ischemia and bleeding ou
Externí odkaz:
https://doaj.org/article/a7c5c39574614ddb8e97e4e329241dd6